Stifel raised the firm’s price target on Insmed (INSM) to $145 from $121 and keeps a Buy rating on the shares following FDA’s recent approval of ...

Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...